Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Oct 30, 2026
TickeronGET DAILY SIGNALS
Why Is Stryker Corporation (SYK) Stock Down -6.38% Today?

Why Is Stryker Corporation (SYK) Stock Down -6.38% Today?

Key Takeaways

  • SYK shares fell roughly 6.4% after the company reported third-quarter results that missed Wall Street expectations and cut its full-year outlook.
  • The primary catalyst was an earnings-driven selloff: revenue of $6.52 billion missed the $6.62 billion consensus, and adjusted EPS of $3.52 came in below the $3.55 expected.
  • A downward revision to 2026 guidance compounded the pressure, with organic sales growth now seen at 6.5%–7.0%, down from a prior range of 8.3%–9.3%.
  • Secondary drivers included soft hip and knee volumes, lingering supply-chain disruption from an earlier cyberattack, and slower adoption of newer products such as Mako RPS and Triathlon Gold.
  • Analysts reacted by trimming price targets, reinforcing the negative market reaction.
  • Traders are now watching fourth-quarter execution, 2027 guidance under incoming CEO Spencer Stiles, and whether surgical volumes stabilize.
  • For additional details on valuation and targets, explore Price Targets, Earnings, and Forecast pages for SYK.
  • To discover the strongest-performing automated strategies under current market conditions, explore Trending AI Robots.

Opening Summary

Stryker Corporation (SYK), a global medical technology company known for orthopaedic implants, surgical equipment, and neurotechnology devices, saw its shares fall sharply on Friday. The stock traded down approximately 6.38%, slipping from a prior close of $311.75 to around $291.87. The decline came after the company reported third-quarter results that missed analyst expectations and lowered its full-year sales and earnings guidance, triggering a broad market selloff in the stock.

Earnings Miss Weighs on the Stock

The immediate driver behind the move was a third-quarter earnings report that fell short of forecasts. Stryker posted revenue of $6.52 billion, up 7.7% year over year but below the $6.62 billion analysts had projected. Adjusted earnings per share came in at $3.52, a roughly 10% increase from the prior-year period but slightly under the $3.55 consensus estimate.

While the magnitude of the headline miss was modest, the market's reaction was outsized because the shortfall touched both the top and bottom lines and was accompanied by a weaker forward view. Net profit on a GAAP basis also declined, reflecting both softer operating performance and a goodwill impairment charge.

Guidance Cut Amplifies the Selloff

The more significant catalyst was management's decision to reduce its outlook. The company now expects 2026 organic net sales growth of 6.5% to 7.0%, down from a prior range of 8.3% to 9.3%. It also trimmed its adjusted EPS forecast to a range of $14.80 to $14.90, below the previous $14.95 to $15.10 and under the consensus estimate near $14.95.

CEO Kevin Lobo acknowledged that the quarter's "good overall performance" nonetheless "fell short" of internal expectations. The guidance reset signaled that headwinds in core orthopaedic markets, rather than being transitory, are expected to persist through the end of the year, prompting investors to reassess the company's near-term growth trajectory.

Segment Weakness and Operational Headwinds

Under the surface, the results revealed uneven performance across divisions. The MedSurg and Neurotechnology segment grew 9.2%, a bright spot driven by strength in endoscopy and medical products. However, the Orthopaedics segment grew just 5.7%, with U.S. knee sales up only 1.3% and U.S. hip sales down 0.6%.

Management cited elevated insurance premiums and deductibles, increased pre-authorization denials, and softer international markets as factors slowing surgical volumes. Lingering supply disruption tied to an earlier cyberattack and slower-than-expected adoption of newer offerings such as Mako RPS and Triathlon Gold added further friction. These issues collectively reinforced concerns that growth is decelerating even as management works to restore momentum.

Analyst Reactions and Market Context

The market reaction was accompanied by a wave of analyst revisions. Several firms trimmed price targets while largely maintaining their ratings, reflecting a more cautious stance on the stock following the guidance cut. The move also occurred against a backdrop in which the broader medical-device sector has faced questions about procedure volume trends and cost pressures.

Trading activity was elevated as investors repositioned, with the stock underperforming the broader market. The decline pushed shares toward levels last seen near the stock's 52-week low, underscoring the magnitude of the de-rating relative to its recent trading range.

What Comes Next for SYK

Looking ahead, attention turns to fourth-quarter execution and whether the company can stabilize hip and knee volumes while sustaining momentum in MedSurg and Neurotechnology. Investors will also focus on the leadership transition, as incoming CEO Spencer Stiles takes over and is expected to provide clearer 2027 guidance early next year.

Key risks include continued softness in surgical procedures, the pace of recovery from the cyberattack-related supply disruption, and the trajectory of newer product launches. While the company maintains a strong balance sheet and a sizable share-buyback program, the path to regaining investor confidence will depend on delivering results that match or exceed its reset expectations.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated standout performance in the current market environment. Tickeron offers hundreds of automated strategies spanning thousands of tickers, each varying by trading style, timeframe, performance metrics, and the symbols they trade. Only the strongest performers under prevailing conditions are featured. Explore the Trending AI Robots page to see which strategies are leading right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SYK

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for SYK turns negative, indicating new downward trend

SYK saw its Momentum Indicator move below the 0 level on November 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 52 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 58%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SYK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 20 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.

The Moving Average Convergence Divergence Histogram (MACD) for SYK turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 22 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

SYK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

SYK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Following a +2.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 178 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

The Aroon Indicator entered an Uptrend today. In 133 of 256 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.211) is normal, around the industry mean (4.142). P/E Ratio (33.491) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1941 Stryker Way
Phone
+1 269 385-2600
Employees
56000
Web
https://www.stryker.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.
Why Is Stryker Corporation (SYK) Stock Down -6.38% Today?